| 1. |
- Luo, Xi, et al.
(författare)
-
ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants
- 2019
-
Ingår i: Blood Advances. - : AMER SOC HEMATOLOGY. - 2473-9529 .- 2473-9537. ; 3:20, s. 2962-2979
-
Tidskriftsartikel (refereegranskat)abstract
- Standardized variant curation is essential for clinical care recommendations for patients with inherited disorders. Clinical Genome Resource (ClinGen) variant curation expert panels are developing disease-associated gene specifications using the 2015 American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) guidelines to reduce curation discrepancies. The ClinGen Myeloid Malignancy Variant Curation Expert Panel (MM-VCEP) was created collaboratively between the American Society of Hematology and ClinGen to perform gene- and disease-specific modifications for inherited myeloid malignancies. The MM-VCEP began optimizing ACMG/AMP rules for RUNX1 because many germline variants have been described in patients with familial platelet disorder with a predisposition to acute myeloid leukemia, characterized by thrombocytopenia, platelet functional/ultrastructural defects, and a predisposition to hematologic malignancies. The 28 ACMG/AMP codes were tailored for RUNX1 variants by modifying gene/disease specifications, incorporating strength adjustments of existing rules, or both. Key specifications included calculation of minor allele frequency thresholds, formulating a semi-quantitative approach to counting multiple independent variant occurrences, identifying functional domains and mutational hotspots, establishing functional assay thresholds, and characterizing phenotype-specific guidelines. Preliminary rules were tested by using a pilot set of 52 variants; among these, 50 were previously classified as benign/likely benign, pathogenic/likely pathogenic, variant of unknown significance (VUS), or conflicting interpretations (CONF) in ClinVar. The application of RUNX1-specific criteria resulted in a reduction in CONF and VUS variants by 33%, emphasizing the benefit of gene-specific criteria and sharing internal laboratory data.
|
|
| 2. |
- Dodson, Lois M., et al.
(författare)
-
From incomplete penetrance with normal telomere length to severe disease and telomere shortening in a family with monoallelic and biallelic PARN pathogenic variants
- 2019
-
Ingår i: Human Mutation. - : Hindawi Limited. - 1059-7794 .- 1098-1004. ; 40:12, s. 2414-2429
-
Tidskriftsartikel (refereegranskat)abstract
- PARN encodes poly(A)‐specific ribonuclease. Biallelic and monoallelic PARN variants are associated with Hoyeraal‐Hreidarsson syndrome/dyskeratosis congenita and idiopathic pulmonary fibrosis (IPF), respectively. The molecular features associated with incomplete penetrance of PARN‐associated IPF have not been described. We report a family with a rare missense, p.Y91C, and a novel insertion, p.(I274*), PARN variant. We found PARN p.Y91C had reduced deadenylase activity and the p.(I274*) transcript was depleted. Detailed analysis of the consequences of these variants revealed that, while PARN protein was lowest in the severely affected biallelic child who had the shortest telomeres, it was also reduced in his mother with the p.(I274*) variant but telomeres at the 50th percentile. Increased adenylation of telomerase RNA, human telomerase RNA, and certain small nucleolar RNAs, and impaired ribosomal RNA maturation were observed in cells derived from the severely affected biallelic carrier, but not in the other, less affected biallelic carrier, who had less severely shortened telomeres, nor in the monoallelic carriers who were unaffected and had telomeres ranging from the 1st to the 50th percentiles. We identified hsa‐miR‐202‐5p as a potential negative regulator of PARN. We propose one or more genetic modifiers influence the impact of PARN variants on its targets and this underlies incomplete penetrance of PARN‐associated disease.
|
|
| 3. |
- Gunja, Sethu Madhava Rao, 1986-, et al.
(författare)
-
Transcriptome analysis of human patients with telomere biology disorders having mutations in PARN gene
-
Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
- Poly(A)-specific ribonuclease (PARN) is a eukaryotic deadenylating enzyme that removes poly(A) tails of RNAs, including mRNAs and ncRNAs. Mutations in human PARN are associated with developmental delay and telomere biology disorders. We have previously described a group of human patients with mutations in PARN that presented heterogeneity in disease phenotypes. Here, we have characterized the transcriptome of these patients by investigating the differential gene expression to identify metabolic pathways that were affected in these patients. Patients with lesions in PARN were all affected in the same metabolic pathways: ribosome/translation, cell-cell adhesion and cell signaling pathways. This suggests that these pathways could be crucial for the development of a severe disease state and influence penetrance of the disease. We also identified major defects in snoRNAs, scaRNAs and miRNAs profiles. Interestingly a miRNA cluster miR-let7c/miR99a/miR-125b was affected in one patient. This miRNA cluster has anti-tumorigenic properties, suggesting that deficiency of PARN could result in the development of cancer. Overall, this study has identified metabolic pathways that are affected in PARN deficient patients. The identified pathways could play a role in development of TBDs.
|
|
